← boardnext 2026-12
OMER
Omeros Corporationdistress 3/10 · well-funded / low risk$9.86+0%today-43% from 52w high
Cardiovascular 1Nephrology 1
Lead: Paroxysmal Nocturnal Hemoglobinuria
Revenue
pre-revenue
Liquidity
$135M
Runway
1.4 yrs
Shares 1y
+6%
Price & events
-18.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+6.9%
1W
-5.9%
1M
-27.1%
3M
-17.4%
6M
+158.1%
1Y
+80.3%
2Y
-30.5%
5Y
-32.1%
All
Overview
- Market Cap
- $713.62M
- Enterprise Value
- $799.61M
- Volume
- 55.34K
- 52 Week Range
- $3.36 – $17.18
- Total Shares
- 72.38M
- Float Shares
- 69.80M
- Short %
- 21.68%
- % Held by Insiders
- 3.56%
- % Held by Institutions
- 44.64%
- RVOL
- 0.03x
- Beta
- 2.55
Pipeline stages · 2 programs
OMS906 study drug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Biological: narsoplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | OMS906 study drug | Paroxysmal Nocturnal Hemoglobinuria | — | recruiting |
| 2026-01 | Phase 2 | OMS906 study drug | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | 20 | recruiting |
| 2025-12 | Phase 2 | Biological: narsoplimab | Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | 18 | recruiting |
| 2025-11-03 | Phase 1 | OMS906 | Paroxysmal Nocturnal Hemoglobinuria | 15 | completed |
Catalyst news & presentations · 6
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026chmp opinionCHMP (EU)narsoplimab · EMA opinion on Marketing Authorization Application for narsoplimabSEC 8-K
- December 26, 2025PDUFAPDUFAnarsoplimab · FDA target action date for narsoplimab BLA, extended from September 25, 2025SEC 8-K
- 2025-11-25partnershipzaltenibart · Exclusive global license to develop and commercialize zaltenibart to Novo Nordisk for $240M upfront plus milestones up to $1.8B and royalties.SEC 8-K
- fourth quarter of 2025regulatory submissionFiled (NDA/BLA)zaltenibart (OMS906) · Closing of asset purchase and license agreement expected in Q4 2025SEC 8-K
- 2025-07-24pdufa extensionnarsoplimab · PDUFA date for narsoplimab BLA extended to December 26, 2025 due to information requestSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $33 (+235% upside) · 1 analysts
- 2026-06-26HC Wainwright & Co.Buy
- 2026-06-10HC Wainwright & Co.Buy
- 2026-05-14HC Wainwright & Co.Buy
- 2026-04-21D. Boral CapitalBuy
- 2026-01-27D. Boral CapitalBuy
- 2026-01-08D. Boral CapitalBuy
Competitors — Paroxysmal Nocturnal Hemoglobinuria
Recent news
- 2026-07-22OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
- 2026-07-21 - GlobeNewswire
- 2026-07-21Omer-Decugis ups stake in Ivorian mango business - Fruitnet
- 2026-07-21Omer-Decugis: Revenue Up by 16.3%, Margins Under Pressure - Idéal Investisseur
- 2026-07-20Omer-Decugis & Cie SA Reports Earnings Results for the Half Year Ended March 31, 2026 - marketscreener.com
- 2026-07-20Omeros repurchases $14.5M of 9.50% convertible notes, total retirements $30.5M - TradingView
- 2026-07-20OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
- 2026-07-20Omer Keinan links with Asher Swissa on ‘1 2 3 4.’ - edmnomad
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.